13F filings

Montanova Capital

Its 13F for Q2 2026, filed Aug 14, 2026.

Formerly SuvrettaThe filing on EDGAR

Share
Download on the App StoreGet it on Google Play

Free on iOS and Android

Scan to get
the app

Biggest moves

Q2 2026, quarter ended Jun 30

Montanova sold its whole $141.5M Apellis Pharmaceuticals stake in Q2 2026.

Valued at Mar 31, the quarter before: a 13F gives no sale price.

SPY SPDR S&P 500 ETF Trust, put+$448.1M
APLS Apellis Pharmaceuticals, sold out−$141.5M
KALV KalVista Pharmaceuticals, sold out−$96.0M
AVLN Avalyn Pharma, new+$82.4M
HUT Hut 8, new+$77.3M
ERAS Erasca, sold out−$55.6M
SNSE Faeth Therapeutics+$49.6M
APH Amphenol, new+$47.5M
DRAM Roundhill Memory ETF, new+$44.5M

Calls and puts in grey: an option is not a buy or a sale of the stock, and its amount is as filed, mostly the value of the shares underneath. Every filed line is in the list below.

13F value

Held on Jun 30, 2026
$5.5B

in 96 positions. $4.8B in shares, plus $709.4M of option notional (calls and puts, not money invested).

Sector mix by disclosed value

  • Healthcare55.4%
  • Technology10.3%
  • Consumer Cyclical5.2%
  • Financial Services4.3%
  • Industrials3.7%
  • Communication Services2.7%
  • Consumer Defensive2.2%
  • Basic Materials1.4%
  • Funds & ETFs0.9%
  • 3 smaller sectors4.5%
  • Options and unclassified (not a sector)13.9%

The grey slice is mostly calls and puts (13.0% of the disclosed value), which get no sector because a put is a position against a company.

Q1 2026 filing$3.9B
Q2 2026 filing$5.5B

+39.7% filing to filing, from price moves and buying or selling: not the fund’s return. Not investment advice.

GetSignal estimate

Two figures, two sources

Assets under management, as reported to the SEC

$7.9B

Regulatory assets under management on Form ADV, filed Mar 19, 2026 by Montanova Capital, LLC. A gross figure: it counts borrowed money and assets a 13F never lists, so it is not the 13F value.

13F stock positions at the latest close

$4.0B

−16.6% on the $4.8B of stock lines filed for Jun 30

If unchanged since Jun 30, 2026: the filing's stock lines at the Nov 12 close. Options and bonds left out; 96.2% of the value priced, the rest carried at its filed value. An estimate of what the filed positions are worth now, not a forecast and not the fund's return. How it is made. Not investment advice.

Sold out

Q2 2026 13F, calls and puts aside
3

positions sold out among the 15 largest moves. Worth $293.1M together at Mar 31, the quarter before.

APLSApellis Pharmaceuticals$141.5M
KALVKalVista Pharmaceuticals$96.0M
ERASErasca$55.6M

Largest holdings

50 largest of 96 positions

A put on SPY is the largest, at 13.0% of the 13F value. The five largest are 35.2%.

HoldingTypeValueShares% of 13F value
SPYSPDR S&P 500 ETF TrustPut$709.4M950,000 shares13.0%
MANEVeradermicsShares$512.5M4,168,970 shares9.4%
ARQTArcutis BiotherapeuticsShares$326.1M12,437,000 shares6.0%
LEGNLegend BiotechShares$204.2M7,070,000 shares3.7%
PVLAPalvella TherapeuticsShares$173.5M1,135,406 shares3.2%
AVBPArriVent BioPharmaShares$156.9M4,515,531 shares2.9%
BNTCBenitec BiopharmaShares$154.5M11,548,351 shares2.8%
BHVNBiohavenShares$153.1M10,286,937 shares2.8%
AMDAdvanced Micro DevicesShares$149.4M257,240 shares2.7%
RCUSArcus BiosciencesShares$147.3M4,776,423 shares2.7%
TSMTaiwan Semiconductor ManufacturingShares$145.5M304,627 shares2.7%
NVDANVIDIAShares$144.2M720,609 shares2.6%
EYPTEyePoint PharmaceuticalsShares$118.6M8,296,375 shares2.2%
SYYSyscoShares$118.0M1,411,550 shares2.2%
GEGE AerospaceShares$116.0M310,262 shares2.1%
IMTXImmaticsShares$113.4M11,190,129 shares2.1%
MGMMGM Resorts InternationalShares$111.2M2,325,360 shares2.0%
METAMeta PlatformsShares$99.0M175,807 shares1.8%
CAPRCapricor TherapeuticsShares$98.6M4,092,784 shares1.8%
KURAKura OncologyShares$94.1M8,575,422 shares1.7%
GLUEMonte Rosa TherapeuticsShares$85.9M3,549,539 shares1.6%
AVLNAvalyn PharmaShares$82.4M2,503,109 shares1.5%
HDHome DepotShares$79.7M226,053 shares1.5%
HUTHut 8Shares$77.3M670,000 shares1.4%
COFCapital One FinancialShares$66.8M333,098 shares1.2%
VMCVulcan MaterialsShares$63.4M214,978 shares1.2%
FERGFerguson EnterprisesShares$58.6M246,758 shares1.1%
ZURAZura BioShares$55.7M9,443,001 shares1.0%
IFRXInflaRxShares$51.4M22,933,910 shares0.9%
AURAAura BiosciencesShares$51.2M7,206,217 shares0.9%
SNSEFaeth TherapeuticsShares$50.5M2,020,103 shares0.9%
MSOSAdvisorShares Pure US Cannabis ETFShares$49.5M9,738,524 shares0.9%
AMZNAmazon.comShares$48.8M204,860 shares0.9%
REPLReplimune GroupShares$48.6M4,389,836 shares0.9%
APHAmphenolShares$47.5M269,300 shares0.9%
SPOTSpotify TechnologyShares$46.7M101,800 shares0.9%
CTNMContineum TherapeuticsShares$46.6M2,841,334 shares0.9%
APOApollo Global ManagementShares$45.3M383,300 shares0.8%
BACBank of AmericaShares$45.0M789,720 shares0.8%
DRAMRoundhill Memory ETFShares$44.5M603,000 shares0.8%
CRNXCrinetics PharmaceuticalsShares$44.4M1,186,279 shares0.8%
CBRSCerebras SystemsShares$38.0M171,900 shares0.7%
DKSDICK'S Sporting GoodsShares$34.3M151,320 shares0.6%
AVGOBroadcomShares$31.6M83,600 shares0.6%
CMPXCompass TherapeuticsShares$30.9M14,101,159 shares0.6%
LXEOLexeo TherapeuticsShares$29.7M6,384,200 shares0.5%
UNHUnitedHealth GroupShares$26.7M64,130 shares0.5%
PROKProKidneyShares$25.2M12,341,266 shares0.5%
WHWKWhitehawk TherapeuticsShares$19.7M4,300,000 shares0.4%
SPCXSpace Exploration TechnologiesShares$17.3M101,200 shares0.3%

% of 13F value is the position's value against the whole disclosed 13F value, so the rows shown here do not sum to 100% unless every position is listed. Calls and puts are shown as filed: most filers give Value as the notional value of the shares underneath, not money invested, but some give the premium paid, and some count contracts rather than shares.

13F moves15 largest moves, line by line

What Montanova Capital bought and sold in Q2 2026

Each filed line against the Q1 2026 filing.
HoldingMoveShare changeEst. amount movedValue after
SPYSPDR S&P 500 ETF TrustAdded put+171.4%+$448.1M$709.4M after
APLSApellis PharmaceuticalsExited-100%-$141.5M$0 after
KALVKalVista PharmaceuticalsExited-100%-$96.0M$0 after
AVLNAvalyn PharmaNewnew+$82.4M$82.4M after
HUTHut 8Newnew+$77.3M$77.3M after
ERASErascaExited-100%-$55.6M$0 after
SNSEFaeth TherapeuticsAdded+5,747%+$49.6M$50.5M after
APHAmphenolNewnew+$47.5M$47.5M after
SPOTSpotify TechnologyAdded+9,155%+$46.2M$46.7M after
DRAMRoundhill Memory ETFNewnew+$44.5M$44.5M after
PFGCPerformance Food GroupTrimmed-96.2%-$41.6M$1.6M after
USFDUS Foods HoldingTrimmed-98.3%-$39.8M$708K after
CBRSCerebras SystemsNewnew+$38.0M$38.0M after
MLYSMineralys TherapeuticsTrimmed-88.7%-$36.8M$4.7M after
DKSDICK'S Sporting GoodsNewnew+$34.3M$34.3M after

A change is this filing measured against the one before it. Est. amount moved is the shares added or sold, priced at the Jun 30, 2026 close. An estimate: a 13F gives no trade prices or dates. For a sold-out position, its value at the previous quarter end. A put gains when the stock falls; a call gains when it rises. Option values are as filed, which for most filers is the notional value of the shares underneath.

Source: Form 13F, filed with the SEC on Aug 14, 2026, for positions held on Jun 30, 2026. A 13F lists US-listed stock and options at their quarter-end value; short sales, cash and most bonds are not in it. Methodology · Guide to Form 13F. Checked for newer filings on Nov 14, 2026. Not investment advice.

Questions

What Montanova Capital holds, what moved and how current the filing is.

What does Montanova Capital hold?

Montanova Capital disclosed 96 positions worth $5.5B in the Q2 2026 13F filing, $709.4M of it option notional counted at the value of the shares underneath. The largest is a put on SPY at 13.0% of the disclosed value. A 13F lists US-listed stock and options on it; short sales and cash are not in it.

What did Montanova Capital buy and sell last quarter?

Comparing the Q2 2026 filing with the quarter before, the largest moves were adding to a put on SPY, selling out of APLS, selling out of KALV and opening a position in AVLN. Changes are measured against the previous filing, not against trades, because a 13F does not disclose trades.

How current is this?

This is the Q2 2026 filing, covering positions held on Jun 30, 2026 and filed with the SEC on Aug 14, 2026. A 13F is due 45 days after the quarter ends, so the most recent filing is always at least six weeks behind the market, and the manager may have changed the book since.

Other managers we track

ranked by stock held
See every manager we track